Enrichment of CD133‐expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival

Thilo Sprenger(University of Göttingen), Torsten Liersch(Universitätsmedizin Göttingen)

Cancer

June 26, 2012

10.1002/cncr.27703

Cited by 57

Related Papers

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

|The Lancet Oncology|2009|960

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial

|The Lancet Oncology|2015|723